Literature DB >> 15496289

Chronic regulation of the expression of gap junction proteins connexin40, connexin43, and connexin45 in neonatal rat cardiomyocytes.

Aida Salameh1, Polin Schneider, Katja Mühlberg, Andreas Hagendorff, Stefan Dhein, Dietrich Pfeiffer.   

Abstract

Gap junction channels form the basis of intercellular communication in the heart. In the working myocardium, the connexin43 (Cx43) is most abundantly found, whereas connexin40 (Cx40) is expressed in the atria and in the conduction system [together with low levels of connexin45 (Cx45)]. However, little is known about the differential regulation of the connexins by pathophysiologically stimuli such as tumor necrosis factor alpha (TNFalpha). Inasmuch as TNFalpha may play a contributory role in the concert of factors involved in the pathophysiology of heart failure and because this cardiac disease often leads to ventricular reentrant arrhythmia, the goal of our study was to find out whether TNFalpha may influence the expression of the cardiac connexins connexin43, connexin40, and connexin45. Neonatal rat cardiomyocytes were exposed to TNFalpha (10, 40, 100, 400, and 1000 pg/ml) for 24 h with or without additional treatment with the mitogenic-activated protein kinase (MAP-kinase) inhibitors SB203580 [4-(4-fluorophenyl)-2-(4-methyl-sulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; 10(-5) M, protein38 mitogenic-activated protein kinase (p38 MAP kinase) inhibitor] or the MEK1 (mitogenic-activated protein kinase/extracellular signal-regulated kinase kinase) inhibitor PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 10(-5) M]. Connexin43, connexin40, and connexin45 expressions were analysed using Western blot analysis, immunohistology, and polymerase chain reaction (PCR) studies (connexin43 and connexin40). TNFalpha induced a concentration-dependent increase in connexin43 (by 2.9+/-0.6, P<0.05, n=5) but not in connexin40 or connexin45 expressions. Both connexins (40 and 45) showed a very low expression near the detection limit. The increases in connexin43 expression could be completely suppressed by SB203580 (0.9+/-0.4, P<0.05, n=5) but not by PD98059. In absence of a stimulating drug, these inhibitors (SB203580 or PD98059) did not affect connexin43 content. Additional PCR experiments revealed increases in connexin43 mRNA under the influence of 100 pg/ml TNFalpha (211+/-38%, P<0.05, n=5), which could be completely suppressed by SB203580. In contrast, the connexin40 expression remained unchanged. From these results, we conclude that TNFalpha can differentially regulate cardiac connexin expression via p38 MAP kinase pathway and thus may alter intercellular communication. This may contribute to the changes observed in heart failure with regard to the formation of an arrhythmogenic substrate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496289     DOI: 10.1016/j.ejphar.2004.09.024

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues.

Authors:  Lucrecia Márquez-Rosado; Joell L Solan; Clarence A Dunn; Rachael P Norris; Paul D Lampe
Journal:  Biochim Biophys Acta       Date:  2011-07-26

2.  Comparison of mRNA expression of transcriptional factors and intercalated disk constituent proteins between in vivo and cultured cardiomyocytes.

Authors:  Takao Nakamura; Zhonggang Feng; Tsubasa Honda; Yasutomo Nomura; Tatsuo Kitajima; Mitsuo Umezu
Journal:  J Artif Organs       Date:  2008-10-05       Impact factor: 1.731

3.  Mitogen-activated protein kinase kinase 4 deficiency in cardiomyocytes causes connexin 43 reduction and couples hypertrophic signals to ventricular arrhythmogenesis.

Authors:  Min Zi; Tomomi E Kimura; Wei Liu; Jiawei Jin; Jonathan Higham; Sanjay Kharche; Guoliang Hao; Ying Shi; Weijian Shen; Sukhpal Prehar; Aleksandr Mironov; Ludwig Neyses; Marti F A Bierhuizen; Mark R Boyett; Henggui Zhang; Ming Lei; Elizabeth J Cartwright; Xin Wang
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

4.  MicroRNA- 1 represses Cx43 expression in viral myocarditis.

Authors:  Hong-Fei Xu; Yu-Jie Ding; Yi-Wen Shen; Ai-Min Xue; Hong-Mei Xu; Cheng-Liang Luo; Bei-Xu Li; Yue-Lin Liu; Zi-Qin Zhao
Journal:  Mol Cell Biochem       Date:  2011-11-02       Impact factor: 3.396

Review 5.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 6.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

7.  The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors.

Authors:  A Salameh; S Krautblatter; S Karl; K Blanke; D Rojas Gomez; S Dhein; D Pfeiffer; J Janousek
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

8.  Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.

Authors:  Esperanza Herradón; Cristina González; José A Uranga; Raquel Abalo; Ma I Martín; Visitacion López-Miranda
Journal:  Front Pharmacol       Date:  2017-05-08       Impact factor: 5.810

9.  Organ explant culture of neonatal rat ventricles: a new model to study gene and cell therapy.

Authors:  A Dénise den Haan; Marieke W Veldkamp; Diane Bakker; Geert J J Boink; Rob B Janssen; Jacques M T de Bakker; Hanno L Tan
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

Review 10.  p38 MAPK Pathway in the Heart: New Insights in Health and Disease.

Authors:  Rafael Romero-Becerra; Ayelén M Santamans; Cintia Folgueira; Guadalupe Sabio
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.